Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| PI15/00449 | Other Grant/Funding Number | Instituto Salud Carlos III Fondo Europeo Desarrollo Regional |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The purpose of this study is to assess the evolution of disease control, health-related quality of life, and the risk of severe asthma exacerbations in children and adolescents with persistent asthma in Spain at short, mid and long-term follow-up. Patient-reported information in this project is collected by computer assisted telephone interviews (CATI) and a mobile application (ARCA App).
Primary Objectives:
Secondary Objectives:
ARCA is a prospective multicenter observational study in children and adolescents with a clinical diagnosis of persistent asthma. This clinical diagnosis of asthma is defined as the presence of wheezing three times in the last year that improves with the use of bronchodilators. Participants are consecutively recruited in outpatient pediatric pulmonology hospital consultations and primary care physicians.
Patient-reported information is obtained by computer-assisted telephone interviews (CATI) and a mobile application (ARCA App). Telephone interviews are performed by trained interviewers to children 8-16 years old and parents/caregivers of children 6-7 years of age, immediately after recruitment and every 6 months. It includes the evaluation of asthma control, prescribed asthma treatment, adherence, and severe asthma exacerbations. Information about inhalation techniques, socioeconomic status, smoking exposure, triggers, use of peak flow, symptom diary, perceived asthma care, adherence attitudes, and beliefs about illness, inhaler and exacerbations is also collected.
The 'ARCA app' combines 3 age versions: parents/guardians (proxy response) for children 6-7 years old, children aged 8-11 years (self-response), and adolescents aged 12-16 years (self-response). The application consists in an interactive chat, simulating a conversation by Short Message Service (SMS) or Instant Messaging Application (WhatsApp) with someone in real time. It includes the monthly administration of 2 questions (global rating of change and severe asthma exacerbations). At the beginning, after downloading the app, and every two months different standardized questionnaires are administered by turns: the EuroQol (EQ-5D), the Pediatric Asthma Impact Scale (PAIS), inhalation techniques scale, and environment support. These latter scales are administered randomly to two groups of equal size, defined within the subsample recruited by each pediatrician.
All the information that each participant answers through the app can be viewed by the pediatrician through a specific platform. The results of the different questionnaires are shown in charts reflecting the patient's answers over time, using the traffic lights code: green for good outcomes, amber for intermediate, and red for poor. Clinical data is registered at recruitment and annually during the follow-up.
Sample size: To detect differences between two groups in the Asthma Control Questionnaire score of 0.3 SD, 175 patients per group would be required to have a statistical power of 80%, at a significance level of 5%.
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Asthma Research in Children and Adolescents - Spanish Cohort | Groups defined according to treatments prescribed during regular clinical practice and to the exposure to inhalation techniques monitoring |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Inhaled Corticosteroids (ICs) | Drug | Any corticosteroid (beclomethasone, budesonide, ciclesonide, fluticasone propionate, fluticasone furoate, mometasone, and triamcinolone) prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma. The daily dose of ICs prescribed will be translated into beclomethasone equivalent. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in symptoms control, measured with the Asthma Control Questionnaire (ACQ) | Symptoms control is measured with the Asthma Control Questionnaire (ACQ-symptoms) only, which assesses the frequency of 5 asthma symptoms (night-time waking, symptoms on waking, activity limitation, shortness of breath, and wheeze) during the previous week on a 7-point Likert scale from 0 (no impairment) to 6 (maximum impairment). The overall score, calculated as the mean of item responses, ranges from 0 to 6. A score >1.5 is considered not well-controlled asthma, and scores <0.75 well-controlled asthma. | 2, 5, 7 and 10 years after inclusion |
| Change from baseline in Health-Related Quality of Life, measured with the EuroQol | The EQ-5D consists of 5 dimensions ("mobility", "looking after myself", "doing usual activities", "having pain/discomfort" and "feeling worried/sad/unhappy). It includes also a visual analogue scale (EQ-VAS) on the general health status from 0 (worst health status) to 100 (best health status possible). The EQ-5D index ranges from 1 (best health state) to negative values (health states valued as worse than death), where 0 is equal to death, allowing the calculation of Quality-Adjusted Life-Years (QALYs). | 2, 5, 7 and 10 years after downloading the ARCA app |
| Number of severe asthmatic exacerbations | As a screening to detect asthma exacerbation, the experience of asthma worsening question is administered through the ARCA app: "In the last month, have you had to take any pill, syrup, oral solution or go to the doctor or hospital, due to asthma worsening?" (Yes/No). If the answer is "yes", a phone call confirms or discards a severe asthma exacerbation through the following questions: "Did you visit or phone your general practitioner, out-of-hours, or walk-in center because your asthma got worse?", "Did you call an ambulance or go to the hospital because of your asthma?", "Did you take steroids tablets (such as Prednisolone or Deltacortril) for at least 2 days because of your asthma?" If the participant answers "yes" to at least one of the 3 questions, an asthma exacerbation is confirmed. These questions were constructed applying the definition of the American Thoracic Society and the European Respiratory Society. |
| Measure | Description | Time Frame |
|---|---|---|
| Change from baseline in adherence to the treatment, measured with the Medication Intake Survey adherence scale-Asthma (MIS-A) | Adherence is assessed separately for each controller inhaler, based on self-reported prescription start date, daily dosage recommendations and 3 questions on controller use over increasing time periods (day before, previous week, and previous month). Percentages of medication used versus prescribed are calculated first for each question, and subsequently as composite scores (0-100). The total score is categorized into complete (100%), intermediate, and low (50%) adherence. Medication abuse (temporary occasional) is also evaluated for each treatment. |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Spanish children and adolescents with persistent asthma seen in the outpatient pediatric pulmonology clinics and primary care pediatricians.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Montse Ferrer Fores, MD,PhD | Parc de Salut Mar | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Centro de Salud de Jerez Sur | Cadiz | Andalusia | 11408 | Spain | ||
| Centro de Salud La Candelaria |
Not provided
| Label | URL |
|---|---|
| Recruitment platform | View source |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
|
|
| Fixed-Dose Combination of Inhaled Corticosteroids and Long- Acting Beta-agonist (ICs/LABA) | Drug | Beclomethasone/formoterol, budesonide/formoterol, fluticasone furoate/vilanterol, fluticasone propionate/formoterol, fluticasone propionate/salmeterol, and mometasone/formoterol. Any of these combinations prescribed by the pediatrician as an inhaled controller medication, for daily management of asthma. |
|
|
| Other treatments | Drug | Low-dose oral corticosteroids, long-acting muscarinic antagonist (tiotropium), low-dose macrolides (azithromycin), leukotrienes receptor antagonists (i.e. montelukast), or biologic agents (i.e. omalizumab). |
|
|
| Inhaler device | Drug | Pressurized metered-dose inhalers (pMDIs), Breath-actuated pMDIs, Dry powder inhalers (DPIs), Nebulizers, Soft Mist Inhalers. |
|
|
| Regularly monitoring of the Inhalation technique through mobile app | Behavioral | App users are randomized within each pediatrician into two groups of equal size defined within the subsample recruited, so that 50% of the participants are allocated to answer the inhalation techniques, and the other 50% are allocated to answer the environment support scales. Once the app is downloaded, at month 2 and every 6 months thereafter the intervention group answers the inhalation techniques scale (group 1) and the control group answers the environment support scale (group 2). |
|
| 5 and 10 years after inclusion |
| 2, 5, 7 and 10 years after inclusion |
| Change from baseline in quality of the inhaler technique, measured with the Inhalation Technique Scale | The Inhalation Technique Scale includes five questions on how often participants perform recommended actions when using inhalers, on a 5-point Likert scale from 0 (never) to 4 (always). The overall score, calculated as the mean of items responses, ranges from 0 to 4 points. Higher values indicate better inhaler technique. | 2, 5, 7 and 10 years after downloading the ARCA app |
| Change from baseline in the Pediatric Asthma Impact Scale (PAIS) | The Patient-Reported Outcomes Measurement Information System (PROMIS) developed the short version of the Pediatric Asthma Impact Scale (PAIS), composed of 8 items assessing the past seven days in a 5-point response scale with the options: never, almost never, sometimes, often, and almost always. The total raw score (adding the values of the response to each question) is translated into a T-score with a mean of 50 and a standard deviation (SD) of 10. A score lower than 50 is one SD lower than the mean of the reference population. | 2, 5, 7 and 10 years after downloading the ARCA app |
| Seville |
| Andalusia |
| 41006 |
| Spain |
| Centro de Salud Torre Ramona | Zaragoza | Aragon | 500013 | Spain |
| Hospital Miguel Servet | Zaragoza | Aragon | 50009 | Spain |
| Hospital Universitario Araba | Alava | Basque Country | 01009 | Spain |
| Centro de Salud Dobra | Torrelavega | Cantabria | 39300 | Spain |
| Health Services Research Group, IMIM-Hospital del Mar Medical Research Institute | Barcelona | Catalonia | 08003 | Spain |
| Hospital del Mar | Barcelona | Catalonia | 08003 | Spain |
| Centro de Atención Primaria de la Vila Olímpica | Barcelona | Catalonia | 08005 | Spain |
| Hospital Vall d'Hebron | Barcelona | Catalonia | 08035 | Spain |
| Hospital Parc Taulí | Barcelona | Catalonia | 08208 | Spain |
| Centro de Salud Segovia | Madrid | Madrid | 28005 | Spain |
| Centro de Salud Canillejas | Madrid | Madrid | 28022 | Spain |
| Centro de Salud Dos de Mayo Móstoles | Madrid | Madrid | 28934 | Spain |
| Centro de Salud República de Argentina | Valencia | Valencia | 46021 | Spain |